Self-Host
Tools / Inside Trading Tracker
Inside Trading Tracker
Track insider trading activity at publicly traded companies to understand how executives are trading their shares.
Anixa Biosciences Inc (ANIX) Insider Trading Activity
Healthcare • Biotechnology • 4 employees
Anixa Biosciences, Inc., a clinical-stage biotechnology company, focuses on the treatment and prevention of cancer. Its therapeutic portfolio consists of an ovarian cancer immunotherapy program being developed in collaboration with Moffitt Cancer Center, which uses a novel type of CAR- T, known as chimeric endocrine receptor T-cell (CER-T) technology. The company's vaccine portfolio includes a novel vaccine being developed in collaboration with Cleveland Clinic to prevent breast cancer primarily triple negative breast cancer (TNBC), the lethal form of the disease, as well as a vaccine to prevent ovarian cancer. Its vaccine technologies focus on immunizing against retired proteins that found to be expressed in certain forms of cancer. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.
Total Value
$227,241.35
Total Shares
94,289
Average Trade Value
$25,249.04
Most Active Insider
Titterton Lewis H Jr
Total Activity: $97,280
Largest Single Transaction
$95,890
by Kumar Amit on Jan 15, 2025
30-Day Activity
8 Transactions
Volume: 78,289 shares
Value: $186,041
|
Name
|
Position
|
Date
|
Shares
|
Value
|
Holdings
|
Type
|
|---|---|---|---|---|---|---|
|
Director
|
Jan 28, 2025 | 5,000 | $14,100 | 120,000 (+4.2%) | Purchase | |
|
Director
|
Jan 24, 2025 | 1,000 | $3,000 | 933,334 (+0.1%) | Purchase | |
|
Director
|
Jan 23, 2025 | 2,000 | $5,820 | 932,334 (+0.2%) | Purchase | |
|
Director
|
Jan 22, 2025 | 2,000 | $6,020 | 930,334 (+0.2%) | Purchase | |
|
Director
|
Jan 21, 2025 | 6,000 | $15,540 | 928,334 (+0.6%) | Purchase | |
|
Director
|
Jan 17, 2025 | 10,000 | $25,700 | 922,334 (+1.1%) | Purchase | |
|
President, Coo, CFO
Officer
|
Jan 15, 2025 | 9,289 | $19,971 | 44,500 (+20.9%) | Purchase | |
|
Chief Executive Officer
Officer
|
Jan 15, 2025 | 43,000 | $95,890 | 559,925 (+7.7%) | Purchase | |
|
Director
|
Oct 22, 2024 | 16,000 | $41,200 | 912,334 (+1.8%) | Exercise/Conversion |